HENDERSON, NV / ACCESSWIRE / December 28, 2018 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price at a breakneck pace. That's why investors are always searching for the next ‘big thing' that could either become FDA approved, acquired, or just make major progress. The companies below are the kinds of opportunities these investors crave.
According to Grand View Research, the global obesity treatment market was valued at $3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. These are just a couple making companies developing weight management solutions so valuable to investors.
One of the more novel approaches to fighting this obesity epidemic is being developed by, BioRestorative Therapies, Inc. (BRTX) (Market Cap: $6.68M Share Price: $0.68) a life sciences company focused on stem cell-based therapies, developing a therapy ''ThermoStem'' using brown adipose (fat) derived stem cells to generate brown adipose tissue (''BAT''). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
Another obesity play, Obalon Therapeutics, Inc. (OBLN) (Market Cap: $54.93M Share Price: $2.42) developing the an FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, just announced that it has received approval from the U.S. Food and Drug Administration (FDA) of the Obalon Navigation System, which eliminates the need to use x-ray when placing the Obalon Balloon System.
Reshape Lifesciences, Inc. (RSLS) (Market Cap: $2.67M Share Price: $0.35), moved away from ballons in favor of lap band technology after announcing the acquisition of the Lap-Band® adjustable gastric band system from Apollo Endosurgery, Inc. and that Apollo Endosurgery has acquired the ReShape Balloon™ product line from ReShape Lifesciences. ReShape Lifesciences will pay Apollo Endosurgery a total cash purchase price of $17 million, with $10.0 million dollars paid at closing and the additional $7.0 million dollars to be paid in three annual installments beginning on the first anniversary of the closing of the transaction.
Novavax, Inc. (NVAX) (Market Cap: $698.7M Share Price: $1.83) recently promoted Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology.
ZIOPHARM Oncology, Inc. (ZIOP) (Market Cap: $238.55M Share Price: $1.68) CEO Laurence Cooper, M.D., Ph.D. will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019, at 9 a.m. PST.
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to received a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communication, LLC